Arbitration against Optimus Drugs settled mutually, no penalty to company

Regulatory & Legal View source PDF Explain this filing

GUJTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹383.00

prior close

₹381.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%-1.8% vs market

Pharmaceuticals peers, median of 166sector-0.2%-2.6% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.4

15m

-0.3

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8-1.0-1.8-0.2-2.6

Next day

-2.6-0.4-2.2-0.3-2.3

-2.8-0.8-1.9-0.3-2.5

-4.1-1.9-2.2-1.3-2.8

-5.2-1.3-3.9-0.8-4.4

-4.3-1.0-3.3-0.7-3.6

-6.2-2.8-3.4-2.9-3.3

15d

-7.7+0.4-8.0-2.1-5.6

-8.7+2.4-11.1-0.8-7.9

+10.6+1.0+9.6-1.1+11.7

+0.3+1.8-1.5-2.7+3.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gujarat Themis Biosyn had initiated arbitration against Optimus Drugs Private Limited over a commercial dispute, as disclosed on 26 June 2026. The company has now informed exchanges that both parties have amicably resolved the matter and will settle it mutually, and the arbitration will be disposed of accordingly. The company will not pay any penalty due to the settlement and there will be no material financial impact.

Likely market impact

Neutral to mildly positive. The dispute is resolved without penalty or material financial hit, removing overhang and uncertainty for shareholders.